Business Context and Reporting Period
Company: Baxter International Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2002
Business Overview: Baxter operates in three strategic segments: Medication Delivery (infusion pumps, anesthesia, oncology), BioScience (biopharmaceuticals, blood collection), and Renal (end-stage kidney disease treatments). The company is headquartered in Deerfield, Illinois.
Key Financial Metrics
| Metric (in millions) | 3 Months Ended June 30, 2002 |
6 Months Ended June 30, 2002 |
3 Months Ended June 30, 2001 |
6 Months Ended June 30, 2001 |
|---|---|---|---|---|
| Net Sales | $2,022 | $3,972 | $1,870 | $3,627 |
| Gross Margin | 45.5% | 45.5% | 44.2% | 44.0% |
| Net Income | $200 | $453 | $253 | $415 |
| Diluted EPS | $0.32 | $0.73 | $0.42 | $0.68 |
| Cash Flow from Operations | N/A | ($31) | N/A | ($37) |
| Cash and Equivalents | $472 | $472 | N/A | N/A |
| Total Debt (Short + Long Term) | $457 | $457 | N/A | N/A |
Note: Cash flow from operations for the six-month period was negative due to working capital changes, despite positive net income.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 8% for the quarter and 10% year-to-date compared to 2001. Excluding currency fluctuations, growth was 9% and 11%, respectively.
- Profitability Decline: Net income decreased 21% for the quarter and increased 9% year-to-date. The quarterly decline was driven by a $51 million in-process research and development (IPR&D) charge and a $70 million impairment charge on investments.
- Segment Performance:
- Medication Delivery: Sales up 15% (quarter) and 13% (YTD); Pretax income up 30% (quarter).
- BioScience: Sales up 7% (quarter) and 12% (YTD); Pretax income up 5% (quarter).
- Renal: Sales down 1% (quarter) and up 1% (YTD); Pretax income up 6% (quarter).
- Accounting Changes: Adoption of SFAS No. 142 eliminated goodwill amortization starting Jan 1, 2002. In 2001, a cumulative effect of accounting change reduced earnings by $52 million (net of tax).
Guidance, Outlook, and Risks
- Management Outlook: Management expects sales growth to accelerate in the second half of 2002. They aim for low-teens sales growth and mid-teens EPS growth for the full year, excluding one-time charges.
- Acquisitions:
- Acquired Fusion Medical Technologies for $161 million (stock) in May 2002, resulting in a $51 million IPR&D charge.
- Agreed to acquire majority of ESI Lederle (Wyeth) for ~$305 million, pending regulatory approval.
- Liquidity: Operational cash flow was negative $351 million for the six months ended June 30, 2002. The company typically generates the majority of annual cash flow in the second half of the year. Net-debt-to-capital ratio increased to 42.7% from 35.9%.
- Risks and Contingencies:
- Legal Proceedings: Significant exposure remains regarding mammary implant litigation (185 lawsuits pending), plasma-based therapies (HIV/Hepatitis C claims), and dialyzer safety issues. Management believes reserves are adequate but future charges could be material.
- Currency: A stronger U.S. dollar negatively impacts reported sales and earnings growth.
Investor Verification Checklist
- One-Time Charges: Verify the impact of the $51 million IPR&D charge (Fusion acquisition) and $70 million investment impairment on adjusted earnings.
- Cash Flow Dynamics: Investigate the negative operating cash flow ($31 million outflow) driven by increases in accounts receivable and inventory.
- Legal Reserves: Review the adequacy of reserves for mammary implant and plasma therapy litigation, noting the potential for charges exceeding current estimates.
- Acquisition Integration: Assess the timeline for revenue contribution from the Fusion and pending ESI Lederle acquisitions.
- Debt Structure: Monitor the net-debt-to-capital ratio (42.7%) and upcoming debt maturities, including the amended convertible debentures.